Diagnostic Testing and Emerging Technologies- G2 Intelligence

A Closer Lab-Patient Connection

By Oscelle Boye, MBiomed | Dec 17, 2024 | 1 min read

Patient access to data from the clinical lab is increasing. What does this mean for those generating it?

An illustration of a male patient interacting with a female laboratory professional on a laptop.

New and Improved: The Latest Research in Disease Screening

By Michael Schubert, PhD | Dec 17, 2024 | 1 min read

New ideas and innovations look beyond conventional screening options to facilitate improved disease diagnosis and patient outcomes

Closeup image of blue and yellow liquid being pipetted intro microwells, illustrating disease screening.

A Lasting Impact: COVID-19 and Cancer Screening

By Michael Schubert, PhD | Dec 17, 2024 | 1 min read

Several years after the onset of the COVID-19 pandemic, labs are still dealing with the effects of missed and delayed screenings

An IV tube and blood test tube sit on a test order form for cancer screening

Test Utilization: ‘Cascades of Care’ Cause Wasteful, Unnecessary and Anxiety-Producing Testing

By Glenn S. Demby | Nov 16, 2019 | 2 min read

...

Subscribe to View

Start a Free Trial for immediate access to this article

Try For Free

Already a member? Log in here

Emerging Tests: New Genetic Tests May Be Better than PSA Screening in Assessing Prostate Cancer Risk

By Glenn S. Demby | Nov 16, 2019 | 2 min read

...

Subscribe to View

Start a Free Trial for immediate access to this article

Try For Free

Already a member? Log in here

Kellison and G2 Intelligence Honor Dr. Sidney Goldblatt

By Glenn S. Demby | Nov 13, 2019 | 2 min read

...

Subscribe to View

Start a Free Trial for immediate access to this article

Try For Free

Already a member? Log in here

Emerging Tests: FDA Issues New Guidance on Using NGS Data to Secure Antiviral Drug & CDx Test Approval

By Glenn S. Demby | Oct 17, 2019 | 2 min read

...

Subscribe to View

Start a Free Trial for immediate access to this article

Try For Free

Already a member? Log in here

FDA Watch: Expanded Label Clearance Opens Cologuard to a Younger Market

By Glenn S. Demby | Oct 17, 2019 | 1 min read

September was an eventful month for one of the hottest products on the consumer genetic test market, the Cologuard multi-target stool DNA test (mtSDNA) for colorectal cancer screening produced by Exact Sciences. The month started badly with the release of a CMS-sponsored research report finding Cologuard “less effective and considerably more costly” than alternatives. Although Exact Sciences quickly criticized the report and its analytical methodology, its stock took a beating.